May 6, 2025 10:44 AM EDT

Lilly to pay up to $415M in ALS deal; Actuate’s mid-stage pancreatic cancer data

ENDPOINTS

Plus, news about Atara Biotherapeutics, Immutep, bluebird bio, OSE Immunotherapeutics, Mersana Therapeutics, Innovent, Biomea Fusion and Trailhead Biosystems:

Eli Lilly does another ALS deal: The …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Lilly to pay up to $415M in ALS deal; Actuate’s mid-stage pancreatic cancer data

ENDPOINTS

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

A new dawn for psychedelics? Compass could be the first to find out

Updated: MD Anderson-allied investment firm targets $250M for second cancer biotech fund

Weeks after TIGIT fail, iTeos decides to wind down

Strand Therapeutics reports promising start for mRNA cancer therapy

Novartis won bidding war for kidney drug as Regulus' top three execs expect to make over $100M combined

From weeks to days: how Aizon Intelligent Agents transform pharma validation

Lil­ly to pay up to $415M in ALS deal; Ac­tu­ate’s mid-stage pan­cre­at­ic can­cer da­ta

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Lilly to pay up to $415M in ALS deal; Actuate’s mid-stage pancreatic cancer data